Charming Medical Ltd
For the period ended Mar 31, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.
FY2026 · Filed Jul 30, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended March 31,2026
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report: _____________
For the transition period from ______ to ________
Commission file number:001-42907
Charming Medical Limited
(Exact name of Registrant as specified in its charter)
British Virgin Islands
(Jurisdiction of incorporation or organization)
Units 1803-1806,18/F, Hang Lung Centre
2-20 Paterson Street, Causeway Bay, Hong Kong
(Address of principal executive offices)
Kit Wong
Tel:+852 2116 1492
Units 1803-1806, 18/F, Hang Lung Centre
2-20 Paterson Street, Causeway Bay, Hong Kong
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Class A Ordinary Shares, par value $0.0001 per share | MCTA | The Nasdaq Stock Market LLC (Nasdaq Capital Market) |
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:15,178,000 Class A Ordinary Shares and 2,000,000 Class B Ordinary Shares issued and outstanding as of March 31, 2026.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
☐ Yes ☒No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
☐ Yes ☒No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
☒Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ |
|---|---|---|
| Emerging growth company ☒ | ||
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
| U.S. GAAP ☒ | International Financial Reporting Standards as issued | Other ☐ |
|---|---|---|
| by the International Accounting Standards Board ☐ |
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
☐ Item 17 ☐ Item 18
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).
☐ Yes☒ No
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
☐ Yes ☐ No
Table of Contents
| Page | ||
|---|---|---|
| PART I | 1 | |
| Item 1. | Identity of Directors, Senior Management and Advisers | 1 |
| Item 2. | Offer Statistics and Expected Timetable | 1 |
| Item 3. | Key Information | 1 |
| Item 4. | Information on the Company | 49 |
| Item 4A. | Unresolved Staff Comments | 72 |
| Item 5. | Operating and Financial Review and Prospects | 73 |
| Item 6. | Directors, Senior Management and Employees | 92 |
| Item 7. | Major Shareholders and Related Party Transactions | 103 |
| Item 8. | Financial Information | 104 |
| Item 9. | The Offer and Listing | 105 |
| Item 10. | Additional Information | 105 |
| Item 11. | Quantitative and Qualitative Disclosures About Market Risk | 124 |
| Item 12. | Description of Securities Other than Equity Securities | 125 |
| PART II | 126 | |
| Item 13. | Defaults, Dividend Arrearages and Delinquencies | 126 |
| Item 14. | Material Modifications to the Rights of Security Holders and Use of Proceeds | 126 |
| Item 15. | Controls and Procedures | 127 |
| Item 16. | [Reserved] | 128 |
| Item 16A. | Audit Committee Financial Expert | 128 |
| Item 16B. | Code of Ethics | 128 |
| Item 16C. | Principal Accountant Fees and Services | 128 |
| Item 16D. | Exemptions from the Listing Standards for Audit Committees | 128 |
| Item 16E. | Purchases of Equity Securities by the Issuer and Affiliated Purchasers | 128 |
| Item 16F. | Change in Registrant’s Certifying Accountant | 128 |
| Item 16G. | Corporate Governance | 129 |
| Item 16H. | Mine Safety Disclosure | 129 |
| Item 16I. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 129 |
| Item 16J. | Insider Trading Policies | 129 |
| Item 16K. | Cybersecurity. | 129 |
| PART III | 130 | |
| Item 17. | Financial Statements | 130 |
| Item 18. | Financial Statements | 130 |
| Item 19. | Exhibits | 130 |
i
INTRODUCTION
Unless otherwise indicated, in this annual report on Form 20-F, references to:
| ● | “Beautylab BVI,” or “Beautylab Group Medical” are to Beautylab Group Medical Limited, a BVI business company, a subsidiary of Charming Medical; |
| ● | “Board of Directors” refers to the board of directors of Charming Medical; |
| ● | “BVI Act” refers to the BVI Business Companies Act, Revised Edition 2020, as amended, supplemented or otherwise modified from time to time; |
| ● | “BVI” refers to the British Virgin Islands; |
| ● | “CAGR” refers to compounded annual growth rate, the year-on-year growth rate over a specific period of time; |
| ● | “Class A Ordinary Shares” refers to our class A ordinary shares, par value US$0.0001 per share, carrying one vote per share; |
| ● | “Class B Ordinary Shares” refers to our class B ordinary shares, par value US$0.0001 per share, carrying 20 votes per share; |
| ● | “China” or the “PRC” refers to the People’s Republic of China, including the Hong Kong and Macau Special Administrative Regions of the People’s Republic of China for the purposes of this annual report only; |
| ● | “Chinese government” or “PRC government” refers to the government of Mainland China for the purposes of this annual report only; |
| ● | “Choliya” refers to Choliya Limited, a company incorporated in Hong Kong on March 7, 2021 with limited liability; |
| ● | “Controlling Shareholder” refers to Ms. Kit Wong; |
| ● | “Dream International Trading” refers to Dream International Trading (Hong Kong) Limited, a company incorporated in Hong Kong on March 7, 2021 with limited liability; |
| ● | “Exchange Act” refers to the U.S. Securities Exchange Act of 1934; |
| ● | “FY2026,” “FY2025”, and “FY2024” refer to fiscal year ended March 31, 2026, 2025, and 2024, respectively; |
| ● | “The Group” refers to Charming Medical and its subsidiaries; |
| ● | “HKD,” “Hong Kong dollar(s),” or “HK$” refer to the legal currency of Hong Kong; |
| ● | “Hong Kong” refers to the Hong Kong Special Administrative Region of the People’s Republic of China for the purposes of this annual report only; |
| ● | “Mainland China” refers to the People’s Republic of China, excluding, for the sole purpose of this annual report, Taiwan, the Hong Kong Special Administrative Region of the People’s Republic of China, and the Macao Special Administrative Region of the People’s Republic of China; |
| ● | “Memorandum and Articles” refers to the second amended and restated memorandum and articles of association of Charming Medical filed on May 27, 2025; |
ii
| ● | “My Beauty Technology” refers to My Beauty Technology Limited, a company incorporated in Hong Kong on September 19, 2019 with limited liability; |
| ● | “Operating Subsidiaries” are to Pilate, My Beauty Technology, Dream International Trading, and Choliya; |
| ● | “Ordinary Shares” refers to our Class A Ordinary Shares and Class B Ordinary Shares; |
| ● | “Pilate” refers to Pilate International Trading Limited, a company incorporated in Hong Kong on July 14, 2016 with limited liability; |
| ● | “PRC laws and regulations” or “PRC laws” refers to the laws and regulations of Mainland China; |
| ● | “SEC” refers to the United States Securities and Exchange Commission; |
| ● | “TCM” refers to traditional Chinese medicine; |
| ● | “TCM-inspired” therapies and products refers to therapies and products that are rooted in and influenced by the principles and practices of Traditional Chinese Medicine (TCM) for the purposes of this annual report; |
| ● | “US$,” “$,” or “U.S. dollars” refers to the legal currency of the United States; |
| ● | “U.S.,” or “United States” refers to the United States of America; |
| ● | “U.S. GAAP” refers to generally accepted accounting principles in the United States; and |
| ● | “We,” “us,” “our,” “the Company,” “our Company,” and “Charming Medical” are to Charming Medical Limited, a BVI business company incorporated on February 28, 2024, as a holding company, and does not include its subsidiaries, Beautylab Group Medical, Pilate, My Beauty Technology, Dream International Trading, Choliya; and when describing Charming Medical’s consolidated financial information for the fiscal years ended March 31, 2026, 2025 and 2024, also include Charming Medical’s subsidiaries as mentioned above. |
Charming Medical is a holding company with operations conducted in Hong Kong through its Operating Subsidiaries in Hong Kong, using the Hong Kong dollar. The reporting currency is U.S. dollars. Assets and liabilities denominated in foreign currencies are translated at year-end exchange rates, income statement accounts are translated at average rates of exchange for the year and equity is translated at historical exchange rates. Since 1983, Hong Kong dollars have been pegged to the U.S. dollars at the rate of approximately HK$7.80 to US$1.00.
iii
Disclosure Regarding FORWARD-LOOKING STATEMENTS
This annual report on Form 20-F contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
You can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements include, but are not limited to, statements about:
| ● | future financial and operating results, including revenues, income, expenditures, cash balances and other financial items; |
| ● | our ability to execute our growth, expansion and acquisition strategies, including our ability to meet our goals; |
| ● | current and future economic and political conditions; |
| ● | our expectations regarding demand for and market acceptance of our subsidiaries’ services; |
| ● | our expectations regarding the expansion of our subsidiaries’ client base; |
| ● | our subsidiaries’ relationships with their business partners; |
| ● | competition in our industries; |
| ● | relevant government policies and regulations relating to our industries; |
| ● | our ability to obtain and maintain all necessary government certifications, approvals, and/or licenses to conduct our business; |
| ● | ability to managing our growth effectively; |
| ● | our capital requirements and our ability to raise any additional financing which we may require; |
| ● | our subsidiaries’ ability to protect their intellectual property rights and secure the right to use other intellectual property that they deem to be essential or desirable to the conduct of their business; |
iv
| ● | the dependence on our senior management and key employees; |
| ● | our ability to hire and retain qualified management personnel and key employees in order to develop our subsidiaries’ business; |
| ● | overall industry and market performance; |
| ● | any recurrence of the COVID-19 pandemic and scope of related government orders and restrictions and the extent of the impact of the COVID-19 pandemic on the global economy, impact it may have on our operations, the demand for our products and services, and economic activity in general; and |
You should read this annual report and the documents that we refer to in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Item 3. Key Information - 3.D. Risk Factors.” and elsewhere in this annual report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
We would like to caution you not to place undue reliance on these forward-looking statements and you should read these statements in conjunction with the risk factors disclosed in “Item 3. Key Information - 3.D. Risk Factors.” Those risks are not exhaustive. We operate in an evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. We do not undertake any obligation to update or revise the forward-looking statements except as required under applicable law. You should read this annual report and the documents that we reference in this annual report completely and with the understanding that our actual future results may be materially different from what we expect.
v
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.